alendronate has been researched along with Fibrous Dysplasia of Bone in 7 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Fibrous Dysplasia of Bone: A disease of bone marked by thinning of the cortex by fibrous tissue containing bony spicules, producing pain, disability, and gradually increasing deformity. Only one bone may be involved (FIBROUS DYSPLASIA, MONOSTOTIC) or several (FIBROUS DYSPLASIA, POLYOSTOTIC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate treatment led to a reduction in the bone resorption marker NTX-telopeptides, and improvement in aBMD, but no significant effect on serum osteocalcin, pain, or functional parameters." | 6.79 | A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. ( Bianco, P; Boyce, AM; Brillante, BA; Collins, MT; Kelly, MH; Kushner, H; Riminucci, M; Robey, PG; Wientroub, S, 2014) |
| "Alendronate treatment led to a reduction in the bone resorption marker NTX-telopeptides, and improvement in aBMD, but no significant effect on serum osteocalcin, pain, or functional parameters." | 2.79 | A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. ( Bianco, P; Boyce, AM; Brillante, BA; Collins, MT; Kelly, MH; Kushner, H; Riminucci, M; Robey, PG; Wientroub, S, 2014) |
| "The degree of pain is highly variable and adults reports more pain than children." | 2.48 | Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. ( Chapurlat, RD; Gensburger, D; Ghilardi, JR; Jimenez-Andrade, JM; Kelly, M; Mantyh, P, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Florez, H | 1 |
| Mandelikova, S | 1 |
| Filella, X | 1 |
| Monegal, A | 1 |
| Guañabens, N | 1 |
| Peris, P | 1 |
| Singh, PT | 1 |
| Burad, D | 1 |
| Hephzibah, J | 1 |
| Paul, TV | 1 |
| Boyce, AM | 1 |
| Kelly, MH | 1 |
| Brillante, BA | 1 |
| Kushner, H | 1 |
| Wientroub, S | 1 |
| Riminucci, M | 1 |
| Bianco, P | 1 |
| Robey, PG | 1 |
| Collins, MT | 1 |
| Lv, M | 1 |
| Li, X | 1 |
| Huang, Y | 1 |
| Wang, N | 1 |
| Zhu, X | 1 |
| Sun, J | 1 |
| Chao, K | 1 |
| Katznelson, L | 1 |
| Chapurlat, RD | 1 |
| Gensburger, D | 1 |
| Jimenez-Andrade, JM | 1 |
| Ghilardi, JR | 1 |
| Kelly, M | 1 |
| Mantyh, P | 1 |
| Lane, JM | 1 |
| Khan, SN | 1 |
| O'Connor, WJ | 1 |
| Nydick, M | 1 |
| Hommen, JP | 1 |
| Schneider, R | 1 |
| Tomin, E | 1 |
| Brand, J | 1 |
| Curtin, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-Controlled Trial of Alendronate in the Treatment of Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome[NCT00001728] | Phase 2 | 40 participants (Actual) | Interventional | 1998-08-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alendronate and Fibrous Dysplasia of Bone
| Article | Year |
|---|---|
Pathophysiology and medical treatment of pain in fibrous dysplasia of bone.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Neoplasms; Fibrous Dysplasia of | 2012 |
1 trial available for alendronate and Fibrous Dysplasia of Bone
| Article | Year |
|---|---|
A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.
Topics: Adolescent; Adult; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Rem | 2014 |
5 other studies available for alendronate and Fibrous Dysplasia of Bone
| Article | Year |
|---|---|
Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Female; Fibroblast Growth Fa | 2018 |
Uncommon cause for chest pain.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Chest Pain; Drug Administration Schedule; Fibr | 2018 |
Inhibition of fibrous dysplasia via blocking Gsα with suramin sodium loaded with an alendronate-conjugated polymeric drug delivery system.
Topics: Alendronate; Animals; Bone Marrow Cells; Cell Culture Techniques; Cell Line; Drug Carriers; Durapati | 2016 |
Use of high-dose oral bisphosphonate therapy for symptomatic fibrous dysplasia of the skull.
Topics: Administration, Oral; Adult; Alendronate; Bone Density Conservation Agents; Dose-Response Relationsh | 2008 |
Bisphosphonate therapy in fibrous dysplasia.
Topics: Administration, Oral; Adult; Aged; Alendronate; Biomarkers; Bone and Bones; Collagen; Collagen Type | 2001 |